Top

Published in:

01-05-2009 | ORIGINAL ARTICLE

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

Authors: David A. Peura, James W. Freston, Marian M. Haber, Thomas O. Kovacs, Barbara Hunt, Stuart Atkinson

Published in: Digestive Diseases and Sciences | Issue 5/2009

Abstract

In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after open-label treatment with lansoprazole 30 mg once daily for 8 weeks and received double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily for up to 1 year. At 1 year, 67% of lansoprazole-treated and 13% of ranitidine-treated patients remained healed (P < 0.001). Lansoprazole-treated patients experienced significantly greater symptom relief (P < 0.001), and, if asymptomatic at entry into the maintenance phase, remained asymptomatic for significantly longer than ranitidine-treated patients (P < 0.001). Symptom status correlated with healing (P = 0.001), supporting the symptom-directed management of EE. Both treatments were well tolerated and no unexpected events occurred. Daily therapy with lansoprazole to prevent the relapse of EE is effective, well tolerated, and superior to ranitidine in the maintenance of healing and symptom relief.

Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion. 1992;51(suppl 1):24–29.PubMedCrossRef

McDougall NI, Johnston BT, Kee F, Collins JSA, McFarland RJ, Love AHG. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996;38:481–486. doi:10.1136/gut.38.4.481.PubMedCrossRef

Heading RC. Review article: diagnosis and clinical investigation of gastro-oesophageal reflux disease. A European view. Aliment Pharmacol Ther. 2004;20(suppl 8):9–13. doi:10.1111/j.1365-2036.2004.02221.x.PubMedCrossRef

Ruigomez A, Garcia Rodriguez LA, Wallander MA. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20:751–760. doi:10.1111/j.1365-2036.2004.02169.x.PubMedCrossRef

DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94:1434–1442. doi:10.1111/j.1572-0241.1999.1123_a.x.PubMedCrossRef

Delaney BC. Review article: prevalence and epidemiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20(suppl 8):2–4. doi:10.1111/j.1365-2036.2004.02219.x.PubMedCrossRef

Holtmann G, Adam B, Liebregts T. Review article: the patient with gastro-oesophageal reflux disease—lifestyle advice and medication. Aliment Pharmacol Ther. 2004;20(suppl 8):24–27. doi:10.1111/j.1365-2036.2004.02224.x.PubMedCrossRef

Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004;4:CD003245. doi:10.1002/14651858.CD003245.pub2.

Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag. 2000;7:29–34.

10.

Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086–2100. doi:10.1016/S0140-6736(06)68932-0.PubMedCrossRef

11.

Peura DA, Lee C, Siepman N, Kovacs TO. Long-term efficacy of symptom-based, titrated dose lansoprazole in preventing relapse of erosive reflux esophagitis in subjects with a recent history of erosive reflux esophagitis. Gastroenterology. 2005;128(suppl 2):A527–A528.

12.

Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903–912.PubMed

13.

Kovacs TO, Lee CQ, Chiu YL, Pilmer BL, Metz DC. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment Pharmacol Ther. 2004;20(8):883–889. doi:10.1111/j.1365-2036.2004.02188.x.PubMedCrossRef

14.

Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of non-antral gastric endocrine growth in man. Digestion. 1988;41:185–200.PubMedCrossRef

15.

Haber M, Amer F, Peura D, Qin Q. Chronic gastritis and erosive esophagitis: prevalence and effect of long-term lansoprazole treatment. Gastroenterology. 2005;128:A527.

16.

Kovacs TOG, Atkinson S, Spalding J, Hunt B. Long-term GERD symptoms and quality-of-life improvement in subjects with healed erosive esophagitis treated for up to 7 years with titrated-dose lansoprazole. Gastroenterology. 2006;130(suppl 2):A454. abstract.

17.

Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27–34. doi:10.1111/j.1572-0241.2001.03443.x.PubMedCrossRef

18.

Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. Ann Intern Med. 1996;124:859–867.PubMed

19.

Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10:529–539. doi:10.1046/j.1365-2036.1996.14156000.x.PubMedCrossRef

20.

Freston JW, Jackson RL, Huang B, Ballard ED. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs. 2002;62:1173–1184. doi:10.2165/00003495-200262080-00004.PubMedCrossRef

21.

Adamek RJ, Behrendt J, Wenzel C. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. Eur J Gastroenterol Hepatol. 2001;13:811–817. doi:10.1097/00042737-200107000-00009.PubMedCrossRef

22.

Richter JE, Fraga P, Mack M, Sabesin SM, Bochenek W. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther. 2004;20:567–575. doi:10.1111/j.1365-2036.2004.02121.x.PubMedCrossRef

23.

Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol. 1999;94:931–936. doi:10.1111/j.1572-0241.1999.989_l.x.PubMedCrossRef

24.

Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:927–935. doi:10.1046/j.1365-2036.2001.01024.x.PubMedCrossRef

25.

Pilotto A, Leandro G, Franceschi M, Ageing and Acid-Related Disease Study Group. Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Aliment Pharmacol Ther. 2003;17:1399–1406. doi:10.1046/j.1365-2036.2003.01593.x.PubMedCrossRef

26.

Fennerty MB, Johnson DA. Heartburn severity does not predict disease severity in patients with erosive esophagitis. MedGenMed. 2006;8(2):6.PubMed

27.

Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2004;2(8):665–668. doi:10.1016/S1542-3565(04)00289-7.PubMedCrossRef

28.

Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc. 2006;54(10):1537–1542. doi:10.1111/j.1532-5415.2006.00899.x.PubMedCrossRef

29.

DeVault KR, Morgenstern DM, Lynn RB, Metz DC. Effect of pantoprazole in older patients with erosive esophagitis. Dis Esophagus. 2007;20:411–415. doi:10.1111/j.1442-2050.2007.00642.x.PubMedCrossRef

30.

Annibale B, Franceschi M, Fusillo M, Beni M, Cesana B, Delle Fave G. Omeprazole in patients with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment. Hepatogastroenterology. 1998;45(21):742–751.PubMed

31.

DeVault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006;4:852–859. doi:10.1016/j.cgh.2006.03.006.PubMedCrossRef

32.

Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omperazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol. 1998;30(1):19–27.PubMed

33.

Hansen AN, Bergheim R, Ageratums H, Lund H, Wiklund I, Moum B. Long-term management of patients with symptoms of gastro-oesophageal reflux disease—a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract. 2006;60(1):15–22. doi:10.1111/j.1368-5031.2006.00768.x.PubMedCrossRef

34.

Oster G, Thompson D, Katz S, et al. The GORD outcomes trial: a randomized study to assess outcomes and costs in primary care practice. Gastroenterology. 1998;114:A32. doi:10.1016/S0016-5085(98)80130-3. abstract.CrossRef

35.

Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs. ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med. 2000;9(7):624–630. doi:10.1001/archfami.9.7.624.PubMedCrossRef

36.

Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61:1801–1833. doi:10.2165/00003495-200161120-00011.PubMedCrossRef

Title: Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine
Authors: David A. Peura
James W. Freston
Marian M. Haber
Thomas O. Kovacs
Barbara Hunt
Stuart Atkinson
Publication date: 01-05-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 5/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0466-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Detection of Neuroendocrine Tumors of the Small Bowel by Double Balloon Enteroscopy

Mutational Analysis of WTX Gene in Wnt/ β-Catenin Pathway in Gastric, Colorectal, and Hepatocellular Carcinomas

Clarifying the Relationship Between ABO/Rhesus Blood Group Antigens and Upper Gastrointestinal Bleeding

Synaptic Plasticity: The New Explanation of Visceral Hypersensitivity in Rats with Trichinella spiralis Infection?

The Effects of Melatonin on Colonic Transit Time in Normal Controls and IBS Patients

The Simultaneous Expression of Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 May Enhance Angiogenesis and Tumor Venous Invasion in Tissues of Colorectal Cancers

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials